This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Autologous Adipose-Derived Stromal Cells Delivered Into the Corpus Cavernous in Patients With Erectile Dysfunction

This study is currently recruiting participants.
See Contacts and Locations
Verified September 2016 by Ageless Regenerative Institute
Information provided by (Responsible Party):
Ageless Regenerative Institute Identifier:
First received: March 12, 2014
Last updated: September 19, 2016
Last verified: September 2016

This will be an open-label, non-randomized, multi-center, patient sponsored study of Adipose-Derived Stromal Vascular Fraction cells (AD-SVF) implantation delivered into the corpus cavernous in patients with Erectile Dysfunction.

The intent of this clinical study is to answer the questions: 1) Is the proposed treatment safe and 2) Is treatment effective in improving the disease pathology of patients with diagnosed Erectile Dysfunction.

Condition Intervention Phase
Erectile Dysfunction Other: Liposuction Biological: AD-SVF Cell Injection Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Into the Corpus Cavernous in Patients With Erectile Dysfunction.

Resource links provided by NLM:

Further study details as provided by Ageless Regenerative Institute:

Primary Outcome Measures:
  • Change from Baseline in Schramek's Grade [ Time Frame: Baseline, 3 months, and 6 months ]
    Schramek's grading system- penile rigidity Grade 1 - No erection Grade 2 - Slight Tumescence Grade 3 - Full volume without rigidity Grade 4 - Sufficient for sexual intercourse Grade 5 - Full erection

Secondary Outcome Measures:
  • Change from Baseline of Penile Doppler [ Time Frame: Baseline and 6 moths ]
  • Improvement in Phallometry Measures [ Time Frame: Baseline, 3 Months, and 6 Months ]
    Air Chamber Measurements/ Circumference Measurements

Other Outcome Measures:
  • Number of Participants with Adverse Events [ Time Frame: Baseline, 3 Months, and 6 Months ]

Estimated Enrollment: 100
Study Start Date: March 2014
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: November 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AD-SVF Cell Injection Other: Liposuction
Liposuction using aspiration syringe and tumescent local anesthesia
Other Name: Lipoaspiration
Biological: AD-SVF Cell Injection
Stem cell implantation will be performed using direct injection into the Corpus Cavernosum with local anesthesia
Other Name: Adipose derived Stromal Vascular Fraction Cell Injection

Detailed Description:
AD-SVF will be collected from the patient's adipose-derived tissue (body fat). Using local anesthesia, Liposuction will be performed to collect the adipose tissue specimen. The adipose tissue is then transferred to the laboratory for separation of the adipose tissue derived stem cells. In addition, peripheral blood will be collected for isolation of platelet rich plasma, which are then combined with the ASC's for direct injection to the Corpus Cavernosum (Penis).

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria

  • Males Age 18 and 80 years.
  • Penile arterial insufficiency and or venous leakage (doppler) at the time o inclusion: PSV <25 cm/sec, PSV >25 cm/sec, EDV>5cm/sec, RI<0,75.
  • Up to date on all age and gender appropriate cancer screening per American Cancer Society

Exclusion Criteria

  • Severe co-morbidities like cardiac insufficiency, congestive cardiac failure (NYHA ≥ III), malignancy, infection, sepsis and bed sores.
  • Life expectancy < 6 months due to concomitant illnesses.
  • Exposure to any investigational drug or procedure within 1 month prior to study entry or enrolled in a concurrent study that may confound results of this study.
  • Active infectious disease. Patients known to have tested positive for HIV, HTLV, HBV, HCV, CMV (IgM > IgG) and/or syphilis will be evaluated by an expert as to patient eligibility based on the patient's infectious status
  • Any illness which, in the Investigator's judgment, will interfere with the patient's ability to comply with the protocol, compromise patient safety, or \ interfere with the interpretation of the study results
  • Patients on chronic immunosuppressive transplant therapy
  • Systolic blood pressure (supine) ≤90 mmHg or greater than 200mmHg
  • Resting heart rate > 100 bpm;
  • Active clinical infection within one week of enrollment.
  • Known drug or alcohol dependence or any other factors which will interfere with the study conduct or interpretation of the results or who in the opinion of the investigator are not suitable to participate.
  • History of cancer (other than non-melanoma skin cancer or in-situ cervical cancer) in the last five years.
  • Unwilling and/or not able to give written informed consent.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02087397

Contact: Janette M Daher 954-7447400 ext 2727
Contact: Sharon McQuillan, MD 305-9332988

United States, Florida
Ageless Regenerative Institute LLC Recruiting
Aventura, Florida, United States, 33180
Contact: Sharon McQuillan, MD    305-933-2988   
Contact: Sharon McQuillan, MD    305-9332988   
Principal Investigator: Sharon McQuillan, MD         
Sponsors and Collaborators
Ageless Regenerative Institute
Principal Investigator: Sharon McQuillan, MD Ageless Regenerative Institute
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Ageless Regenerative Institute Identifier: NCT02087397     History of Changes
Other Study ID Numbers: AD-US-ED-001
Study First Received: March 12, 2014
Last Updated: September 19, 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by Ageless Regenerative Institute:
Stem Cell
Erectile Dysfunction

Additional relevant MeSH terms:
Erectile Dysfunction
Sexual Dysfunction, Physiological
Genital Diseases, Male
Sexual Dysfunctions, Psychological
Mental Disorders processed this record on August 22, 2017